GSA Capital Partners LLP Makes New Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

GSA Capital Partners LLP purchased a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 31,437 shares of the biopharmaceutical company's stock, valued at approximately $625,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Los Angeles Capital Management LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 159.2% during the third quarter. Los Angeles Capital Management LLC now owns 200,282 shares of the biopharmaceutical company's stock valued at $3,982,000 after acquiring an additional 123,020 shares during the period. Meritage Portfolio Management increased its position in shares of Catalyst Pharmaceuticals by 121.7% during the 3rd quarter. Meritage Portfolio Management now owns 42,914 shares of the biopharmaceutical company's stock worth $853,000 after purchasing an additional 23,554 shares in the last quarter. Assetmark Inc. lifted its holdings in Catalyst Pharmaceuticals by 2.4% during the 3rd quarter. Assetmark Inc. now owns 72,245 shares of the biopharmaceutical company's stock valued at $1,436,000 after purchasing an additional 1,704 shares during the last quarter. CWA Asset Management Group LLC acquired a new position in Catalyst Pharmaceuticals in the third quarter valued at about $534,000. Finally, Summit Global Investments grew its stake in Catalyst Pharmaceuticals by 2.6% during the third quarter. Summit Global Investments now owns 77,292 shares of the biopharmaceutical company's stock worth $1,537,000 after buying an additional 1,923 shares during the last quarter. Institutional investors own 79.22% of the company's stock.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, Director David S. Tierney sold 15,000 shares of the company's stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total transaction of $301,500.00. Following the completion of the sale, the director now owns 348,874 shares in the company, valued at approximately $7,012,367.40. The trade was a 4.12 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 11.00% of the stock is currently owned by company insiders.

Catalyst Pharmaceuticals Trading Up 1.1 %

Catalyst Pharmaceuticals stock opened at $20.82 on Tuesday. The company has a market cap of $2.48 billion, a PE ratio of 17.64, a PEG ratio of 3.17 and a beta of 0.75. Catalyst Pharmaceuticals, Inc. has a 1 year low of $13.00 and a 1 year high of $24.27. The company's 50-day moving average is $20.99 and its two-hundred day moving average is $18.37.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on CPRX. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, August 9th. Stephens began coverage on Catalyst Pharmaceuticals in a research note on Monday. They issued an "overweight" rating and a $35.00 price objective on the stock. Truist Financial raised their target price on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a "buy" rating in a research note on Monday, November 11th. Citigroup upped their price target on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a "buy" rating in a research report on Friday, August 9th. Finally, HC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $31.14.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.